A Double-blind, Randomized Phase 2 Controlled Trial of Intradermal Hepatitis B Vaccination With a Topical Toll-like Receptor 7 Agonist Imiquimod, in Patients on Dialysis
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

A Double-blind, Randomized Phase 2 Controlled Trial of Intradermal Hepatitis B Vaccination With a Topical Toll-like Receptor 7 Agonist Imiquimod, in Patients on Dialysis

Hung, Ivan Fan-Ngai;Yap, Desmond Yat-Hin;Yip, Terence Pok-Siu;Zhang, Ricky Ruiqi;To, Kelvin Kai-Wang;Chan, Kwok-Hung;Tang, Sydney Chi-Wai;Lui, Sing-Leung;Levin, Yotam;Kochba, Efrat;Lau, Johnson Yiu-Nam;Yuen, Man-Fung;Chan, Tak-Mao;Yuen, Kwok-Yung;
clinical infectious diseases pp. -
162
fan-ngaiclinicala

Abstract

This study demonstrated that topical imiquimod (TLR7 agonist) before intradermal hepatitis B vaccination was safe, with significantly better seroprotection than

Keywords

Access

URL:
https://doi.org/10.1093/cid/ciaa804

Citation

ID: 111103
Ref Key: fan-ngaiclinicala
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
111103
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
4/5
Blockchain Upload Locked

Complete all 5 checklist items to tokenize your article

Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store